Literature DB >> 1835601

Early morphological detection of estramustine cytotoxicity measured as alteration in cell size and shape by a new technique of microperifusion.

K G Engström1, K Grankvist, R Henriksson.   

Abstract

The present study describes a new microscopic perifusion technique for detecting momentary alterations in cell volume and shape. The method has been applied for evaluating early signs of cytotoxicity following chemotherapeutic treatments. The effects of estramustine phosphate (EMP) have been evaluated. EMP is a complex between oestradiol-17 beta and the alkylating agent nor-nitrogen mustard and has recently demonstrated a marked cytotoxicity against malignant glioma cells. The results showed a concentration-dependent increase in cell size and a concomitant decrease in shape factor following EMP-treatment of glioma cells. These changes correlated with cytotoxicity evaluated as cell proliferation and cell membrane alterations shown by 86Rb fluxes and ultrastructural visible membrane damage. The colon cancer line HT-29 displayed no reactions at all following EMP treatment. It is suggested that acute alterations in cell morphology and shape display a strong correlation to the cytotoxicity of EMP encountered by traditional cell culture systems. The findings are discussed with respect to cell membrane disturbances caused by EMP and its potential role as an early test of cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1835601     DOI: 10.1016/0277-5379(91)90099-y

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  The bleb formation of the extracellular pseudopodia; early evidence of microtubule depolymerization by estramustine phosphate in glioma cell; in vitro study.

Authors:  D Yoshida; M Noha; K Watanabe; T Bergenheim; R Henriksson; A Teramoto
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

2.  Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study.

Authors:  D Yoshida; S Hoshino; T Shimura; H Takahashi; A Teramoto
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

Review 3.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 4.  Estramustine in malignant glioma.

Authors:  A T Bergenheim; R Henriksson; J M Piepmeier; D Yoshida
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

5.  Computerized detection of morphological changes to glioma cells during estramustine and ion-channel blocker perifusion.

Authors:  P Behnam-Motlagh; O Jonsson; K G Engström; R Henriksson; K Grankvist
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain--suggesting an apoptotic cell death.

Authors:  C Vallbo; T Bergenheim; A Bergh; K Grankvist; R Henriksson
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.